content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001243514</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001607678</issuerCik>
        <issuerName>Viking Therapeutics, Inc.</issuerName>
        <secFileNumber>001-37355</secFileNumber>
        <issuerAddress>
          <com:street1>9920 PACIFIC HEIGHTS BLVD, SUITE 350</com:street1>
          <com:city>SAN DIEGO</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>858-704-4660</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>SINGLETON J MATTHEW</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Director</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>common</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>Oppenheimer &amp; Co Inc</name>
          <address>
            <com:street1>85 Broad Street</com:street1>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10004</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>20786</noOfUnitsSold>
        <aggregateMarketValue>1195735.00</aggregateMarketValue>
        <noOfUnitsOutstanding>110268210</noOfUnitsOutstanding>
        <approxSaleDate>08/14/2024</approxSaleDate>
        <securitiesExchangeName>NASDAQ</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>common</securitiesClassTitle>
        <acquiredDate>04/28/2015</acquiredDate>
        <natureOfAcquisitionTransaction>NQSO Grant</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>20786</amountOfSecuritiesAcquired>
        <paymentDate>08/14/2024</paymentDate>
        <natureOfPayment>n/a</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <remarks>8/14 selling pursuant to Rule 10b5-1 trading plan on file dated May 16 2024 - POA on file</remarks>
      <noticeSignature>
        <noticeDate>08/14/2024</noticeDate>
        <planAdoptionDates>
          <planAdoptionDate>05/16/2024</planAdoptionDate>
        </planAdoptionDates>
        <signature>J. Matthew Singleton</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2945}]
text: 144
  0001243514
  XXXXXXXX
  LIVE
  0001607678
  Viking Therapeutics, Inc.
  001-37355
  9920 PACIFIC HEIGHTS BLVD, SUITE 350
  SAN DIEGO
  CA
  92121
  858-704-4660
  SINGLETON J MATTHEW
  Director
  common
  Oppenheimer & Co Inc
  85 Broad Street
  New York
  NY
  10004
  20786
  1195735.00
  110268210
  08/14/2024
  NASDAQ
  common
  04/28/2015
  NQSO Grant
  issuer
  N
  20786
  08/14/2024
  n/a
  Y
  8/14 selling pursuant to Rule 10b5-1 trading plan on file dated May 16 2024 - POA on file
  08/14/2024
  05/16/2024
  J. Matthew Singleton